The idea of implementing a unique device was born at the University Research, Innovation and Service Center (EKIK) of the University of Óbuda in Budapest and the university’s János Neumann Faculty of Informatics, in line with the strategic direction of research and development of the University's cyber-medical systems.
Researchers at the University are working at a brisk pace to develop a mass ventilator that can be used to treat a large number of coronavirus patients with up to 5, 10, 50, or even more of them in critical condition at the same time, even in a camp environment. Since the beginning of March, more and more domestic and foreign researchers, students and industry players have been joining the charity, non-profit MassVentil Project research development initiated by the BioTech Research Center and the Antal Bejczy Center for Intelligent Robotics (both of EKIK).
As the researchers explain the mass ventilator concept, during mass respiration, patients are connected to a modular or monolithically designed centralized ventilator system. The system can be designed and installed in a pre-built or ad hoc manner (in medical / non-medical facilities such as wards, sports grounds, gyms, etc.). The mass ventilator system is designed for the combined management of inhalation and exhalation gases (production, temperature / humidity / pressure adjustment, filtration, etc.). During inhalation and exhalation, the air is filtered in both directions in one or more steps.
The management of respiratory gases (filtration, temperature control, humidity control, pressure control, safety control, etc.) is carried out in a distributed manner under centralized control in multiple locations within the mass ventilator system.


Leave a Reply Cancel reply
Top 5 Articles
Sharing Business Experience December 10, 2022
Hungarian Inflation Rate - the Highest in Europe December 16, 2022
Another Korean Battery Supplier Appears in Hungary November 17, 2022
In Strategic Partnership with the Client January 2, 2023
Mobility is Electric for ŠKODA December 6, 2022
No comment yet. Be the first!